What did H.C. Wainwright do in the Feb 24, 2026 note for FULC analyst rating?

H.C. Wainwright maintained a **Buy** on FULC on **February 24, 2026**, citing supportive PIONEER data for pociredir but providing no new price target.

Does the maintained Buy include a new FULC price target?

No, the Feb 24, 2026 note maintained **Buy** without publishing a new **FULC price target**, leaving valuation ranges unchanged for now by Wainwright.

How should investors use the FULC analyst rating in their decisions?

Treat a maintained **Buy** as continued analyst conviction, not a fresh upgrade. Combine the FULC analyst rating with pipeline milestones, cash metrics, and your risk tolerance.

What is Meyka AI’s current view on FULC analyst rating?

Meyka AI rates FULC at **B+**, reflecting benchmark and sector comparisons and analyst consensus; this complements but does not replace personal research.

Analyst Ratings

H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026

ByHuzaifa Zahoor February 25, 2026February 25, 2026

H.C. Wainwright maintained a Buy rating on Fulcrum Therapeutics, Inc. (FULC) on February 24, 2026 after reviewing PIONEER data for pociredir. This FULC analyst rating reflects a continued bullish stance rather than a fresh upgrade or downgrade. The firm emphasized the drug’s differentiated profile while not publishing a new price target. The market reaction showed a short-term pullback of -6.92% ($-0.64), and FULC’s market cap stands at $464,275,623. Meyka AI rates FULC with a grade of B+, combining benchmark and consensus metrics into a single view